These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 33671562)

  • 21. Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update.
    del Campo M; Mollenhauer B; Bertolotto A; Engelborghs S; Hampel H; Simonsen AH; Kapaki E; Kruse N; Le Bastard N; Lehmann S; Molinuevo JL; Parnetti L; Perret-Liaudet A; Sáez-Valero J; Saka E; Urbani A; Vanmechelen E; Verbeek M; Visser PJ; Teunissen C
    Biomark Med; 2012 Aug; 6(4):419-30. PubMed ID: 22917144
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A systematic review of salivary biomarkers in Parkinson's disease.
    De Bartolo MI; Belvisi D; Mancinelli R; Costanzo M; Caturano C; Leodori G; Berardelli A; Fabbrini G; Vivacqua G
    Neural Regen Res; 2024 Dec; 19(12):2613-2625. PubMed ID: 38595280
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Early diagnosis of mild cognitive impairment and Alzheimer's disease based on salivary lactoferrin.
    Carro E; Bartolomé F; Bermejo-Pareja F; Villarejo-Galende A; Molina JA; Ortiz P; Calero M; Rabano A; Cantero JL; Orive G
    Alzheimers Dement (Amst); 2017; 8():131-138. PubMed ID: 28649597
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evolution of Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Early Parkinson's Disease.
    Irwin DJ; Fedler J; Coffey CS; Caspell-Garcia C; Kang JH; Simuni T; Foroud T; Toga AW; Tanner CM; Kieburtz K; Chahine LM; Reimer A; Hutten S; Weintraub D; Mollenhauer B; Galasko DR; Siderowf A; Marek K; Trojanowski JQ; Shaw LM;
    Ann Neurol; 2020 Sep; 88(3):574-587. PubMed ID: 32542885
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cerebrospinal Fluid Biomarkers of Cognitive Decline in Parkinson's Disease.
    Johar I; Mollenhauer B; Aarsland D
    Int Rev Neurobiol; 2017; 132():275-294. PubMed ID: 28554411
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Unraveling Pathophysiological Mechanisms of Parkinson's Disease: Contribution of CSF Biomarkers.
    Farotti L; Paolini Paoletti F; Simoni S; Parnetti L
    Biomark Insights; 2020; 15():1177271920964077. PubMed ID: 33110345
    [TBL] [Abstract][Full Text] [Related]  

  • 27. What is the Clinical Significance of Cerebrospinal Fluid Biomarkers in Parkinson's disease? Is the Significance Diagnostic or Prognostic?
    Kim D; Paik JH; Shin DW; Kim HS; Park CS; Kang JH
    Exp Neurobiol; 2014 Dec; 23(4):352-64. PubMed ID: 25548535
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cerebrospinal fluid alpha-synuclein as a biomarker for Parkinson's disease diagnosis: a systematic review and meta-analysis.
    Gao L; Tang H; Nie K; Wang L; Zhao J; Gan R; Huang J; Zhu R; Feng S; Duan Z; Zhang Y; Wang L
    Int J Neurosci; 2015; 125(9):645-54. PubMed ID: 25202803
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Salivary biomarkers for the diagnosis and monitoring of neurological diseases.
    Farah R; Haraty H; Salame Z; Fares Y; Ojcius DM; Said Sadier N
    Biomed J; 2018 Apr; 41(2):63-87. PubMed ID: 29866603
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Parkinson's and Lewy body dementia CSF biomarkers.
    Parnetti L; Paciotti S; Farotti L; Bellomo G; Sepe FN; Eusebi P
    Clin Chim Acta; 2019 Aug; 495():318-325. PubMed ID: 31051162
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Plasma neuronal exosomes serve as biomarkers of cognitive impairment in HIV infection and Alzheimer's disease.
    Pulliam L; Sun B; Mustapic M; Chawla S; Kapogiannis D
    J Neurovirol; 2019 Oct; 25(5):702-709. PubMed ID: 30610738
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cerebrospinal fluid tau and amyloid-β1-42 in patients with dementia.
    Skillbäck T; Farahmand BY; Rosén C; Mattsson N; Nägga K; Kilander L; Religa D; Wimo A; Winblad B; Schott JM; Blennow K; Eriksdotter M; Zetterberg H
    Brain; 2015 Sep; 138(Pt 9):2716-31. PubMed ID: 26133663
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cerebrospinal fluid biomarkers for Parkinson's disease - a systematic review.
    Andersen AD; Binzer M; Stenager E; Gramsbergen JB
    Acta Neurol Scand; 2017 Jan; 135(1):34-56. PubMed ID: 26991855
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Saliva, an easily accessible fluid as diagnostic tool and potent stem cell source for Alzheimer's Disease: Present and future applications.
    Reale M; Gonzales-Portillo I; Borlongan CV
    Brain Res; 2020 Jan; 1727():146535. PubMed ID: 31669827
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cerebrospinal Fluid and Plasma Biomarkers in Neurodegenerative Diseases.
    Seino Y; Nakamura T; Kawarabayashi T; Hirohata M; Narita S; Wakasaya Y; Kaito K; Ueda T; Harigaya Y; Shoji M
    J Alzheimers Dis; 2019; 68(1):395-404. PubMed ID: 30814356
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cerebrospinal Fluid Biomarkers for Target Engagement and Efficacy in Clinical Trials for Alzheimer's and Parkinson's Diseases.
    Parnetti L; Eusebi P; Lleó A
    Front Neurol Neurosci; 2016; 39():117-23. PubMed ID: 27463974
    [TBL] [Abstract][Full Text] [Related]  

  • 37. How many biomarkers to discriminate neurodegenerative dementia?
    Sancesario GM; Bernardini S
    Crit Rev Clin Lab Sci; 2015; 52(6):314-26. PubMed ID: 26292074
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A top-down proteomic approach reveals a salivary protein profile able to classify Parkinson's disease with respect to Alzheimer's disease patients and to healthy controls.
    Contini C; Fadda L; Lai G; Masala C; Olianas A; Castagnola M; Messana I; Iavarone F; Bizzarro A; Masullo C; Solla P; Defazio G; Manconi B; Diaz G; Cabras T
    Proteomics; 2024 Feb; 24(3-4):e2300202. PubMed ID: 37541286
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biomarkers in Parkinson's disease (recent update).
    Sharma S; Moon CS; Khogali A; Haidous A; Chabenne A; Ojo C; Jelebinkov M; Kurdi Y; Ebadi M
    Neurochem Int; 2013 Sep; 63(3):201-29. PubMed ID: 23791710
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CSF biomarkers β-amyloid, tau proteins and a-synuclein in the differential diagnosis of Parkinson-plus syndromes.
    Constantinides VC; Paraskevas GP; Emmanouilidou E; Petropoulou O; Bougea A; Vekrellis K; Evdokimidis I; Stamboulis E; Kapaki E
    J Neurol Sci; 2017 Nov; 382():91-95. PubMed ID: 29111028
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.